Key facts
- It has raised $1.4M; the latest was Early Stage VC ($1.4M) in Dec 2025.
- Notable investors include Chongqing Industry Investment Fund, Liangjiang Venture Capital, Triwise Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Hanpei Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Hanpei Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hanpei Bio
Developer and researcher of pharmaceuticals for pets intended to serve the pet drug industry. The company offers research and development of various types of drugs for chronic inflammation, pain, cardiovascular disease, tumors, and other common diseases in elderly pets, thereby enhancing treatment efficacy, ensuring safety standards, and supporting long-term wellness for companion animals.
- Sector
- Healthcare
- HQ
- Chongqing, China
- Founded
- 2022
- Website
- hanpets.cn/
- Ownership
- Privately Held (backing)
Hanpei Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hanpei Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hanpei Bio in its N-PORT filings yet. We sweep new filings monthly.